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Abstract As a new human immunodeficiency virus type 1
(HIV-1) vaccine approach, the live-attenuated measles virus
(MV) Schwarz vaccine strain was genetically engineered to
express the F4 antigen (MV1-F4). F4 is a fusion protein com-
prising HIV-1 antigens p17 and p24, reverse transcriptase and
Nef. This study assessed the toxicity, biodistribution and shed-
ding profiles of MV1-F4. Cynomolgus macaques were intra-
muscularly immunized one or three times with the highest dose
of MV1-F4 intended for clinical use, the reference (Schwarz)
measles vaccine or saline, and monitored clinically for 11 or
85 days. Toxicological parameters included local and systemic
clinical signs, organ weights, haematology, clinical and
gross pathology and histopathology. Both vaccines were well
tolerated, with nomorbidity, clinical signs or gross pathological
findings observed. Mean spleen weights were increased after
three doses of either vaccine, which corresponded with in-
creased numbers and/or sizes of germinal centers. This was
likely a result of the immune response to the vaccines. Either
vaccine virus replicated preferentially in secondary lymphoid
organs and to a lesser extent in epithelium-rich tissues (e.g.,
intestine, urinary bladder and trachea) and the liver. At the
expected peak of viremia, viral RNA was detected in some
biological fluid samples from few animals immunized with
either vaccine, but none of these samples contained infectious
virus. In conclusion, no shedding of infectious viral particles
was identified in cynomolgus monkeys after injection of
MV1-F4 or Schwarz measles vaccines. Furthermore, no toxic
effect in relation to the MV vaccination was found with these
vaccines in this study.
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Introduction
The development of a safe and effective prophylactic vaccine
against human immunodeficiency virus type I (HIV-1) is a
global health priority. During the past two decades, significant
efforts have been made to develop such a vaccine. Among the
few candidate HIV-1 vaccines tested in large Phase IIb or III
clinical trials, only the RV144 trial, evaluating a recombinant
canarypox vector prime and HIV-1 gp120 protein boost,
showed a modest efficacy (31 %) against HIV-1 acquisition
(reviewed by McElrath and Haynes 2010; McMichael et al.
2010). Although ultimately, a preventive vaccine against
HIV-1 inducing sterile immunity would be optimal, vaccines
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that would reduce viral load and disease progression by in-
duction of strong and polyfunctional T cell responses should
also prove beneficial (McMichael et al. 2010).
Live attenuated measles virus (MV) vaccine strains, such as
the widely used and strongly immunogenic Schwarz strain
(Griffin 2007), are replicating RNAviruses (Paramyxoviridae
family), capable of inducing long-lived antibody and memory
T cell responses (Ovsyannikova et al. 2003; Vandermeulen et
al. 2007). Besides being highly efficacious, these vaccines are
also recognized as safe (WHO 2009), as MV replicates in the
cytoplasm and does not integrate into the host cell genome.
Moreover, reversion of the vaccine genome into a pathogenic
form has never been observed. The experience accumulated
with these vaccines in the past 50 years, and their capacity to
induce both CD4+ and CD8+ T cells, render recombinant MV
vectors an attractive platform for vaccines aimed to induce T
cell responses specific for the HIV-1 transgene. For several of
these vaccines expressing HIV-1 antigens, the immunogenicity
has been preclinically demonstrated (Combredet et al. 2003;
Guerbois et al. 2009; Liniger et al. 2009; Lorin et al. 2004).
We constructed the HIV-1 vaccine candidate MV1-F4,
using an in vivo replication-competent MV vector (Combredet
et al. 2003) derived from the Schwarz vaccine strain, to
generate recombinant MV expressing the F4 antigen. F4 is a
fusion protein comprising the clade B viral antigens p17,
p24, reverse transcriptase and the regulatory protein Nef.
Combined with AS01 (a liposome-based Adjuvant System
containing 3-O-desacyl-4′-monophosphoryl lipid A (MPL)
and QS21; Garçon et al. 2007), this F4 antigen was shown
to induce potent polyfunctional CD4+ Tcell responses in HIV-
seronegative volunteers (Van Braeckel et al. 2011).
We conducted a study of the biodistribution, shedding
and single- and repeated-dose toxicity of one or three intra-
muscular (IM) immunizations with MV1-F4 in cynomolgus
macaques. The potential intrinsic toxicity of MV1-F4 was
studied, as well as the potential immune-mediated toxicity
resulting from the host response to the vaccine. The resulting
toxicity and biodistribution profiles, including any target
organs identified, could be used to guide clinical safety moni-
toring, while the shedding profile is crucial for determining the
potential of infectious viral dissemination by future vaccine
recipients, and thus of person-to-person transmission of the
virus. The biodistribution, shedding and toxicity profiles of
the MV1-F4 vaccine were compared to those of either the
reference vaccine (the live attenuated monovalent Schwarz
MV vaccine Rouvax), or saline.
Humans are the natural hosts of MV. Measles pathogenesis
has traditionally been studied in non-human primates as no
suitable alternative models exist. Live attenuated MV vac-
cines are generally non-infectious in rodents, except for cotton
rats (in which MV replication is restricted to the lungs) and
transgenic mice (which reproduce only limited aspects of MV
pathogenesis) (de Swart 2008). In the current study, we used
(MV-seronegative) cynomolgus monkeys. This species is
highly sensitive to MV infection and able to develop patho-
logic lesions and clinical symptoms comparable to those in
human MV infections (Kobune et al. 1996). Moreover, their
size permits the administration of a full human vaccine dose.
As none of the known Schwarz strain virus traits, including
viral envelope proteins, were altered for the construction of
the MV1-F4 vector, we hypothesized that the toxicological
profile, tropism and shedding capacity of MV1-F4 is similar
to those of the parental strain (as represented by the reference
vaccine). In addition, we hypothesized that both vaccine
viruses have the potential to spread into a large variety of
organs, as attenuated MV strains can use the CD46 receptor
(which is ubiquitously expressed in both humans and cyno-
molgus macaques; Sakurai et al. 2008), in addition to the
receptors used by wild-type MV (Dorig et al. 1993). Wild-
type MV strains use primarily the signaling lymphocyte
activation molecule (SLAM/CD150) expressed on certain
immune cells, and likely other low-affinity receptors to
enter CD150-negative epithelial cells (Tatsuo et al. 2000b;
Watanabe et al. 2010). As a result, these strains replicate
predominantly in lymphoid organs and epithelial tissues
(Griffin 2007; Takeda 2008). Consequently, MV1-F4 and
Rouvax were expected to spread not only to the latter organs
and tissues, but also to other parts of the body.
Materials and methods
Vaccines
The MV vector pTM-MV-Schw that was used to construct
the MV1-F4 recombinant virus has been described pre-
viously (Combredet et al. 2003). This vector contains an
infectious MV cDNA corresponding to the anti-genome of
the Schwarz MV vaccine strain. An additional transcription
unit (ATU) was inserted into pTM-MV-Schw in order to
sub-clone the F4 fusion protein sequence. F4 has been
described previously (Van Braeckel et al. 2011) and comprises
HIV-1 subtype B antigens p24 (BH10), RT (HXB2), Nef
(Bru-Lai) and p17 (BH10). The ATU contains a cloning-site
cassette inserted into a copy of the original N-P intergenic
region of the MV genome. This region contains the cis-acting
sequences required for transcription of the viral P gene, en-
abling the recombinant MV to express the F4 protein like a
measles gene. The ATU was introduced into the plasmid
backbone by site-directed mutagenesis between the MV P
and M genes, resulting in the plasmid pTM-MVSchw-
ATU2_F4co_mut. MV1-F4 virus was rescued from the
pTM-MVSchw-ATU2_F4co_mut plasmid using a helper
cell-based system developed at the Institut Pasteur. Briefly,
helper HEK293 cells expressing both the T7-RNA polyme-
rase and the SchwarzMVN and P proteins were co-transfected
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with the pTM-MVSchw-ATU2_F4co_mut cDNA and a plas-
mid expressing the Schwarz MV polymerase L. Subsequently,
transfected HEK293-T7-MV helper cells were gently har-
vested and co-cultured with MRC-5 cells for the amplification
of the MV1-F4 virus. Virus titers were determined by end-
point titration on Vero cells and were expressed as 50 % cell
culture infectious dose (CCID50)/ml.
The selected route of administration (IM) and dose were
identical to those intended to be used in the first MV1-F4
clinical trial, with the dose-level representing the highest
intended human dose. One-dose and three-dose schedules
were used, with the three-dose schedule representing the
number of doses to be used in the clinical study, plus one.
One milliliter of MV1-F4 vaccine (viral titer 1.6×104
CCID50/ml) was injected intramuscularly. The reference
vaccine, the commercial (Schwarz) MV vaccine Rouvax
(Sanofi-Aventis, Paris, France) was used according to the
manufacturer’s procedure for IM administration, with each
vaccine dose containing 3.9×103 CCID50 of the Schwarz
measles vaccine. This virus titer was determined with the
same assay as was used for the MV1-F4 vaccine (endpoint
titration on Vero cells). All injections were administered in
the thigh muscle.
Animals and husbandry
The study included purpose-bred cynomolgus monkeys
(Macaca fascicularis), aged either 2–3 years (males and
females) or 7–12 years (sexually mature males), obtained
from Noveprim Ltd (Port Louis, Mauritius) that were sero-
negative for anti-MVantibodies. During the full experimen-
tation period, the animals were housed in a dedicated
primate unit under controlled environmental conditions.
Due to the biosafety level of the MV1-F4 candidate vaccine
(class 2, group II), they were housed individually in stain-
less steel cages (level A2, L2 confinement) and appropriate
precautions were established. The study was conducted in
compliance with the European regulations regarding the
protection of animals used for experimental and other scientific
purposes, and an ethical committee reviewed the study plan
before the initiation of the study.
Study design
The study design followed the guidelines published by the
European Medicines Agency (EMA) as well as other rele-
vant guidelines (EMEA 1995, 2000; WHO 2005). All
experiments were performed under good laboratory practices
(GLP) conditions.
Animals were inoculated and monitored at the laborato-
ries of the Centre International de Toxicologie (CIT; Evreux,
France). Of the 42 monkeys included in the study, 18 young
males and 18 young females were allocated to treatment
groups 1–6 (Table 1). Animals were allocated to groups
(by sex) using a computerized randomization procedure
(CITOX software, developed in-house at CIT, Evreux,
France). In addition, six sexually mature males (three per
group) were allocated to treatment groups 7 and 8 using the
same randomization procedure, and were only used for
collection of semen and peripheral blood mononuclear cells
(PBMC), as well as for selected clinical observations (body
weight, body temperature and food consumption). Treat-
ments included 3.9×103 CCID50 of Rouvax, 1.6×10
4
CCID50 of MV1-F4 vaccine, or saline, and were adminis-
tered according to either a one-dose schedule (injection at
day 1) or a three-dose schedule (injections at days 1, 29 and
57). Monkeys were monitored clinically until sacrifice
(groups 1–6) or until return to laboratory stock at day 85
(groups 7 and 8). Upon completion of the observation
period, animals of groups 1–6 were sedated with ketamine
hydrochloride (Imalgène, Mérial, Lyon, France), then anes-
thetized with thiopental and sacrificed by exsanguination.
Necropsy was performed at two time-points, either within
the expected peak of viremia (10 days after the first vaccine
dose (day 11) for groups 1–3) or when clearance of infec-
tious MV was expected to have occurred (represented by
28 days after the third dose [day 85] for groups 4–6)
(Auwaerter et al. 1999; Pan et al. 2005; Permar et al.
2003). Single- and repeated-dose toxicity was assessed at
various time points (Table 2). Shedding and post-mortem
analyses were conducted at Texcell (Evry, France). All other
procedures were conducted at CIT.
In-life procedures
Animals were monitored at least twice daily for mortality,
morbidity and clinical signs of toxicity. Toxicological
parameters included dermal reactions at the injection sites,
body weight, food consumption, rectal body temperature,
electrocardiography and ophthalmology. Complete clinical
examinations were performed pre-treatment and thereafter
once weekly. Sedation, used for electrocardiography, oph-
thalmology and occasionally for weighing, was done by IM
administered ketamine hydrochloride (Imalgène).
At 3 and 24 h after each immunization, dermal reactions,
including edema and erythema formation, were evaluated
using the Draize scale, and any other lesions were noted.
Reactions persisting for 48 h after immunization were eval-
uated daily until disappearance.
Electrocardiographic examinations were performed using
a Cardioline Delta 3 Plus and Cardiovit AT-6 (Schiller AG,
Baar, Switzerland) with standard leads I–III, starting with
determining the heart rate, PQ and QT intervals and the
QRS-complex duration on lead II.
Ophthalmology included assessment of pupillary light
reflexes using tropicamide (Mydriaticum, Théa, Clermont-
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Ferrand, France), examination of appendages, optic media
and fundus by indirect ophthalmoscopy (Oméga 180, Heine,
Germany) and of anterior segments and lenses (portable slit-
lamp biomicroscope, model SL-15; Kowa, Japan).
Clinical pathology
Peripheral blood samples were collected without sedation at
different time points after the first and the third dose (Ta-
ble 2), in tubes containing EDTA, sodium citrate or lithium
heparin (for haematology, coagulation parameters or blood
biochemistry, respectively).
Haematology (i.e., erythrocyte count, haemoglobin (HB),
mean and packed cell volumes, mean cell HB concentration,
mean cell HB, thrombocytes, leucocytes (differential) and
reticulocytes) was determined by ADVIA 120 haematology
analyser (Siemens, Saint-Denis, France). Leukocyte diffe-
rential analysis (with cell morphology) was assessed in blood
smears stained with May–Grünwald–Giemsa. Coagulation
parameters (i.e., prothrombin time, activated partial throm-
boplastin time and fibrinogen) were measured with an
ACL300 coagulation analyzer (Beckman Coulter, Instrumen-
tation Laboratory, France). Complete blood biochemistry was
assessed by the ADVIA 1650 Chemistry System (Siemens)
using whole blood.
Urinalysis (including volume, pH, specific gravity, pro-
teins, glucose, ketones, bilirubin, nitrites, blood (HB) and
urobilinogen) was done using a Clinitrek 500 urine chemistry
analyzer (Siemens).
Anti-MV antibody response
Blood samples for assessment of humoral responses were
taken at prevaccination and days 11, 29, 56, 67 and 85. Anti-
MV humoral responses in sera were measured using an
anti-MV enzyme-linked immunosorbent assay (ELISA)
adapted from the commercial immunoassay Enzygnost
Anti-Measles Virus/Ig (Dade-Behring, Illinois, USA). A
peroxidase-labelled anti-monkey immunoglobulin (Ig) se-
condary antibody (Rockland, Pennsylvania, USA) was used
in the assay. Animals were considered to be responders if
they were seropositive for anti-MV antibodies, i.e., if the
absorbance (measured at 490/620 nm) exceeded the cut-off
value, for a serum dilution of 1/500. The cut-off values
(percentile 100) were determined per gender for sera collected
prior to vaccination (serum dilution 1/500), and were found to
be equal to 1.74 and 1.22 for sera from female and male
monkeys, respectively.
Gross pathology, organ weights and histopathology
At necropsy, organs were weighed and subjected to macro-
scopic and microscopic examination. The selection of
organs to be examined for gross pathology and histopathol-
ogy analyses followed the applicable European and interna-
tional guidelines (EMEA 1995, 2000; WHO 2005). Of this
selection, the following organs were weighed: adrenals,
brain, epididymides, heart, kidneys, cervical and iliac lymph
nodes, liver, lungs with bronchi, ovaries, pituitary gland,
prostate, spleen, testes, thymus, thyroid with parathyroid
and uterus. Ratios of organ weight to body weight (at
necropsy) were calculated. For gross pathology, the external
surface of the body, orifices, the neck with organs and
tissues, the cranial cavity with surfaces of the brain and
spinal cord and the thoracic, abdominal and pelvic cavities
with their contents were examined. For histopathological
examination, 4-μm-thick sections of tissues were stained
with haematoxylin and eosin.


















1 3 M, 3 F NaCl 0 Day 1 Day 11 Days 0, 4, 11 (A)
2 3 M, 3 F MV1-F4 1.6×104 Day 1 Day 11 Days 0, 4, 11 (A)
3 3 M, 3 F Rouvax 3.9×103 Day 1 Day 11 Days 0, 4, 11 (A)
4 3 M, 3 F NaCl 0 Days 1, 29, 57 Day 85 Days 0, 4, 11, 29, 56, 60, 67, 85 (A)
5 3 M, 3 F MV1-F4 1.6×104 Days 1, 29, 57 Day 85 Days 0, 4, 11, 29, 56, 60, 67, 85 (A)
6 3 M, 3 F Rouvax 3.9×103 Days 1, 29, 57 Day 85 Days 0, 4, 11, 29, 56, 60, 67, 85 (A)
7 3 mature M MV1-F4 1.6×104 Days 1, 29, 57 Day 85 Days 0, 4, 11, 29, 56, 60, 67, 85 (B)
8 3 mature M Rouvax 3.9×103 Days 1, 29, 57 Day 85 Days 0, 4, 11, 29, 56, 60, 67, 85 (B)
M/F male/female, CCID50 50 % cell culture infectious dose
a Pretreatment 0 day 0; days 4, 11 and 2903, 10 and 28 days after the first dose, respectively; day 5601 day prior to the third dose; days 60, 67 and
8503, 10 and 28 days after the third dose, respectively
b (A) PBMC, serum, throat swabs, saliva, nasal swabs, urine and vaginal secretion; (B) PBMC, semen
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Sample processing for biodistribution and shedding
analyses
The selection of organs to be examined for biodistribution
analyses followed the applicable European and international
guidelines (EMEA 1995, 2000; WHO 2005). For biodistri-
bution analyses, tissue samples (3×3×3 mm3) were dissected
out, rinsed with cold phosphate-buffered saline (PBS) and
snap-frozen in cryotubes in liquid nitrogen.
For shedding analyses, selected excretions and biological
fluids (i.e., semen [only for groups 7 and 8], serum, urine,
throat and nasal swabs, saliva, vaginal secretion and faeces)
and PBMC were collected. Throat swabs, saliva, nasal secre-
tions and vaginal secretions were conserved in M4RT tubes
(Remel, Oxoid, Cedex, France) at −70 °C. Semen and faeces
were directly frozen in cryotubes and conserved at −70 °C.
Immediately after collection, urine was centrifuged (800×g,
10 min, 4 °C) and the pellet was resuspended in PBS and stored
at −70 °C. PBMC were isolated from EDTA blood samples by
gradient centrifugation and frozen in PBS (−70 °C). To obtain
serum, blood was collected in plain tubes, incubated (20 min,
room temperature) and centrifuged (3,000×g, 10 min, 4 °C).
RT-qPCR analysis
Samples of organs, tissues, excretions and biological fluids
were used for RNA extraction and MV N-specific, quantita-
tive reverse transcriptase (RT) PCR analysis (RT-qPCR).
Briefly, cDNA was synthesized from the RNA templates,
and then amplified by qPCR specific for the MVN gene. This
gene is identical in both vaccine viruses used in this study.
Frozen organ samples were homogenized using a Tissue
Lyser (30 Hz for ≥2 min; Qiagen, Valencia, CA) and kept on
ice. Samples were then lysed using 1 ml of Qiazol lysis
reagent (Qiagen). Frozen PBMC, excretions and biological
fluids were directly (for urine, serum, throat swabs, nasal
swabs and vaginal secretion), or with a 1/45 dilution factor (for
semen) submitted to RNA extraction. Faeces was resuspended
into PBS to 1/10 (v/v), centrifuged, and the supernatant was
filtered (0.22 μm).
Table 2 Toxicology recording time points












Pre × × × × ×






11g × × ×
29 × × ×
30 ×
56 ×




85g × × ×
a Body weights: recorded at pre-treatment, days 1 and 4 and then once weekly until study end. Food consumption: estimated daily from 5 days
before start throughout the study
b Dermal observations at the injection sites were recorded at 3 and 24 h after each vaccination
c Performed for groups 4–6 only
d On days 1 and 57, tests were done just before and 1 h post immunization. A test at day 85 was done before sacrifice for only one animal
e Blood sampling for clinical pathology performed for groups 1–6 only
f At day 55 or day 56, blood samples for haematology, coagulation parameters and blood biochemistry were taken before immunisation. On day 85,
samples were taken before necropsy
g Day 11, day 85 0 time points of termination of the animals of groups 1–3, groups 4–6 respectively
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Total RNA was extracted from the samples using an
RNeasy 96 kit with the Biorobot 3000 (both Qiagen) and
reagents and protocols recommended by the manufacturer.
Briefly, the lysed samples in 0.2 ml of chloroform were
homogenized (15 s), left at room temperature for 2–3 min
and centrifuged (12,000×g, 15 min, 5 °C). The aqueous
phase was transferred to 96-well plates and placed on the
Biorobot for automatic extraction (by vacuum or centrifu-
gation). Ethanol (600 μl, 70 % (v/v)) was added to each
well. After mixing, samples were placed in the column for
RNA adsorption on the membranes. After three wash steps
(once with 800 μl RW1 buffer and twice with 800 μl RPE
buffer), columns were centrifuged (5,600×g, 10 min). RNA
was then eluted with 60 μl elution buffer (RNase free water)
and stored at temperatures below −70 °C.
RT and qPCR were performed using the AgPath-ID One-
step RT-PCR kit (Applied Biosystems, Inc., Foster City, CA)
and the LightCycler 480 and software version 1.5.0.39 (Roche
Applied Sciences). The forward primer was MeN_TMF(5′-
GCGAGAGCTGCCCATCTTC), the reverse primer was
MeN_TMR (5′-ACTCCGTTGCAGTGTCAATGTC) and
the forward MeN_TMP probe was (6-FAM)~AACCGGCA
CACCC~(NFQ), with the fluorogenic probe located in the
region bracketed by forward and reverse primers. Cycling
conditions were 45 °C for 10 min, 95 °C for 10 min, and
45 cycles of 95 °C for 15 s and 60 °C for 45 s, followed by
40 °C for 2 min. The standard curve and RT-qPCR parameter
determination was performed using an in vitro transcript RNA
template with the sequence of the N gene of the measles
vector. MV1-F4 suspension (GSK; EF4MA001A, viral titer
4.2 log CCID50/ml, 7.2 log genome equivalent (geq)/ml,
diluted to 104 copies geq), was used as positive extraction
control. Negative (RNase/DNase free H2O) and positive ex-
traction controls were run in quadruplicate and duplicate
reactions, respectively. MV1-F4 RNA recovery was assessed
by N-specific RT-qPCR after spiking each type of tissue
with MV1-F4 at various concentrations, and ranged from
90 % to 100 %. The presence of MV1-F4 RNA was
considered positive if the measurements exceeded the limit
of detection (LOD) of 100 geq/reaction, and if the accep-
tance criteria (error <0.2, efficiency>90 % and crossing
point <45) were fulfilled. The LOD was defined as the lowest
amount of copies that can be detected (but not necessarily
quantified as an exact value) with 95 % probability. All
samples were tested once.
In vitro infectivity and immunofluorescence assays
All samples in which a RT-qPCR signal was detected (either
confirmed [above LOD], or at a very low level [below
LOD]) were submitted to an in vitro infectivity assay. The
presence of infectious viral particles for all fluids except
semen was considered positive for values exceeding the
LOD of 10 CCID50/well (with 95 % probability). Neverthe-
less, the assay was designed to detect one infected cell that
propagates the virus to its adjacent cells, resulting in a
plaque forming unit (as aided by the presence of agarose
in the culture medium). Therefore, it was assumed that the
system was able to detect 1 CCID50/well (but with a prob-
ability of detection of less than 95 %). However, for this to
occur at least 10 CCID50 should be present in the inoculum,
in order to allow the adsorbtion onto the cells. For semen,
validation of the infectivity assay could not be conducted
due to high bacterial contamination.
Vero cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM)–5 % fetal calf serum (FCS)–4 mM gluta-
mine. Before seeding the cells, a sterilized (ethanol, UV)
coverslip (18×18 mm2) was placed in each well. One day
before inoculation, 6-well plates were seeded with 4×105
Vero cells/well. Biological fluid samples were diluted (1:
15.625 for serum, 1:10 for all other fluids) in dilution medium
(DMEM–1% antibiotics) and 700 μl of each fluid sample was
added to Vero cells for 2 h of inoculation (37 °C, 5 % CO2).
Inoculum was then removed and 2 ml of survival medium
(DMEM–2 % FCS–4 mM of glutamine–1 % antibiotics)
supplemented with 1 % (v/v) low-melting agarose was added.
The plates were incubated (37 °C, 5 % CO2) for 6 days. As a
positive control, Vero cells were inoculated with100 CCID50
of MV1-F4 viral suspension (as described above) and diluted
in 700 μl dilution medium. As a negative control, Vero cells
were inoculated with 700 μl dilution medium.
The presence of infectious viral particles was revealed by
immunofluorescence assay (IFA), using an antibody directed
against the measles N protein. The acceptance criteria of
the assay were the absence or presence of fluorescence,
respectively, in the negative or the positive controls.
After 6 days of incubation, the culture medium was re-
moved and 2 ml of 4 % paraformaldehyde was added (15 min,
5 °C). The slides were washed with PBS and incubated
overnight with 2 % goat serum at 5 °C. Next, 100 μl of the
primary antibody (mouse anti-MV-N monoclonal antibody
[# MAB8906; Chemicon, Temecula, CA, USA]), diluted
1:200 in PBS–2 % goat serum–0.1 % saponin, was added to
each well (60 min, room temperature). After washing twice
with PBS, 100 μl of the secondary antibody (goat anti-mouse
F(ab′)2-Cy3 [# LU1513615; Jackson ImmunoResearch, West
Grove, PA, USA]) diluted to 1:500 in PBS–2 % goat serum–
0.1 % saponin, was added to each well. After incubation
(45 min, room temperature), coverslips were washed twice
with PBS, rinsed with water, mounted on a slide using Vecta-
shield DAPI mounting medium (Vector Laboratories, Peter-
borough, UK) and inspected under fluorescence microscope.
Positivity or negativity was checked by the presence or
absence of fluorescence, respectively.
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Statistical analysis
The following sequence was used for statistical analyses
of body weights, body temperatures and electrocardiogra-
phy, haematology, blood biochemistry and urinalysis data.
A test of normality using the Kolmogorov–Lilliefors test
was performed, followed by log-transformation of the
data if normality assumptions were not satisfied. Assess-
ment of homogeneity of variance was performed using
the Bartlett test. If the homogeneity of variance was not
rejected, the treatment groups were compared to the con-
trol group using the Dunnett test, in other cases the Dunn
test was applied. The same procedure, but without log-
transformation of the data, was performed for the statis-
tical analysis of organ weights using PathData software




No mortality or morbidity was observed in any of the groups
(Table 3). The only clinical effect recorded for a vaccine
group was marked dehydration (without diarrhoea) in a
Rouvax-treated male on days 56–62, which resolved within
the following 2 days. Scab formation was noted in one
Rouvax-treated male each of the one-dose and three-dose
groups. These effects were incidental, self-limiting and of a
mild-to-moderate nature, and therefore considered toxico-
logically irrelevant. In the controls of group 4, incidental
vomiting (day 1; one male) and very slight erythema (days
1–3, one female) were noted.
For both sexes, mean body weights of vaccine and control
groups were not significantly different and remained virtually
Table 3 Toxicology results
Parameters MV1-F4 Rouvax Controls
Mortality None observed None observed None observed
Clinical observations
Local reactogenicity
-Dermal observations IS None Scabs (2 M, groups 3 and 6) Slight erythema (1 F, group 4, days 1–3)
Systemic reactogenicity
-Body weights No changes No changes No changes
-Food consumption No vaccine-related effect No vaccine-related effect No changes
-Body temperature No vaccine-related effect No vaccine-related effect No changes
-Electrocardiography No vaccine-related effect No vaccine-related effect Sinusal arrhythmia (1 F)
pretreatment
-Ophthalmology No vaccine-related effect No vaccine-related effect Hypopigmented fundus (2 F)
-Other effects None observed Dehydration (1 M, days 56–64) Vomiting (1 M, group 4, day 1)
Clinical pathology
-Haematology No vaccine-related effect No vaccine-related effect No changes
-Coagulation parameters Mean aPTT time in males shorter than
in controls (day 56)
No vaccine-related effect No changes
-Blood biochemistry No vaccine-related effect Mean CK value in males higher
than in controls (day 85)
No changes
-Urinalysis No vaccine-related effects No vaccine-related effects No changes
Gross pathology No vaccine-related macroscopic findings No vaccine-related macroscopic findings No changes
Organ weights - Elevated absolute and relative spleen weights on days 11
(in males) and day 85 (in both genders, statistically significant
in Rouvax-treated females).
No changes
-Elevated mean absolute and relative weights of cervical and iliac
lymph nodes, mainly in treated males (both vaccines; days 11 and 85).
-Lowered absolute and relative thymus weights in treated males (both
vaccines; days 11 and 85).
Histopathology -Increased size of white pulp for both sexes on day 11 (MV1-F4) and
day 85 (both treatments, corresponding with higher spleen weights).
Increased size of white pulp in females
(day 11).
-Increased sizes/numbers of germinal centers in mandibular
lymph nodes in MV1-F4 treated males (day 11).
Increased sizes/numbers of germinal centers in
mandibular lymph nodes in females
(day 85).
Changes reported as compared to baseline
M/F male/female, IS Injection site, aPTT activated partial thromboplastin time, CK creatine kinase
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constant, with minor increases between days 0 and 85. Apart
from scheduled fasting days prior to procedures, the indivi-
dual food consumption was generally 75–100 % of the daily
ration across groups. On days when animals were sedated, the
consumption was typically 25–50 % of the daily ration, and
occasionally 0 % (on days 1 and 57 for nearly all females of
groups 4–6, and on day 84 for two Rouvax-treated males).
These fasting periods had no impact on body weights and
were similar across control and vaccine groups, and thus
considered to be unrelated to immunization.
Mean rectal temperatures of groups of vaccinated males
were not significantly different from those of the control groups
at all time points. For females, the sporadically noted statistical
differences between groups remained within the ranges com-
monly recorded in animals of this age housed in similar expe-
rimental conditions. Consequently, no treatment-related effects
on body temperature were observed in the study.
There were no treatment-related abnormalities in the
qualitative and quantitative electrocardiography parameters.
Although low-amplitude R and P waves and high- or low-
amplitude, biphasic and negative T waves were noted, these
findings were isolated, observed both prior to and post treat-
ment, and occurred in both controls and immunized groups.
They were also commonly observed in non-treated cynomol-
gus monkeys kept under similar laboratory conditions. No
statistical differences in quantitative parameters (PQ, QRS
and QT intervals and heart rates) were recorded between any
of the groups. Sinusal arrhythmia was observed prior to treat-
ment in one female in the control group.
No relevant ophthalmological findings were observed in
any treatment group. In two control females, a hypopigmented
fundus was noted at all three observation time points.
Clinical pathology
No treatment-related effects were noted for haematological,
blood clinical chemistry and urinalysis parameters in any of
the vaccine groups. At all time points, values for control and
immunized animals of both genders were similar. On day 56, the
mean activated partial thromboplastin time (aPTT) forMV1-F4-
treated males was slightly (15 %) shorter than for control males
(i.e., 17.4 vs. 20.4 s; p<0.01), which was not observed for
females of this group or for other treatment groups. Prothrombin
times (PT) were unaffected by immunization. For blood bio-
chemistry parameters, the only relevant finding was a higher
mean creatine kinase (CK) activity in Rouvax-treated males
compared to control males (i.e., 3,760 vs. 1,010 IU/l; p<0.05)
on day 85, due to elevated values recorded for two animals.
Anti-MV humoral response
To evaluate the humoral responses induced by both vaccines,
anti-MV (Ig) antibody responses were measured in sera. Ten
days after a single dose (day 11), responses were undetectable
in the majority (87 %) of immunized animals (Fig. 1). How-
ever, a 100% seroconversion rate was observed in the animals
of the three-dose Rouvax or MV1-F4 groups (groups 5–8)
from 28 days after the first dose (day 29) onwards. This
suggests that the anti-MV humoral responses may not have
been fully developed at day 11, as confirmed by the kinetics of
these responses in the vaccinated animals.
Viral shedding in body fluids
To assess the potential release of infectious MV1-F4 viral
particles in PBMC, excretions and biological fluids (inclu-
ding serum, urine, throat- and nasal swabs, saliva, vaginal
secretions, semen and faeces), samples were first tested for
the presence of MV viral sequences by N-specific RT-qPCR
assay. All samples in which viral RNAwas detected, even if
below the defined LOD, were then tested further using an in
vitro infectivity assay.
Of the eight time points at which shedding analysis was
performed, MV viral RNA was only detected at day 11 in
some of the vaccine groups. At this time point, all signals in
animals of all vaccine groups were below the LOD (Table 4),
with the exception of one positive result in the three-dose
Rouvax group. In the MV1-F4 groups, viral RNA was
detected (below the LOD) in faeces from two males of the
one-dose group and in urine and vaginal secretions from one
female of the three-dose group. In the Rouvax groups, viral
RNA was detected in throat secretions (above the LOD,
three-dose group), in faeces, throat swabs, vaginal secretion
and serum (below the LOD, three-dose group), in nasal
secretions (below LOD, both groups) and in PBMC (below
the LOD, three-dose group and group of mature males). No
positive results were detected in any of the samples of the
control groups or in saliva samples of any treatment group.
In the in vitro infectivity assay and at the LOD of
10 CCID50/well, no infectious viral particles were recovered
from any sample in which viral RNA had been detected,
with acceptance criteria (i.e., negative and positive controls
showing respectively negative and positive results) being
fulfilled.
Biodistribution in organs and tissues
The potential presence of viral RNA in organs and tissues
from vaccinated monkeys was detected by RT-qPCR spe-
cific for the N gene. This gene is identical in both vaccine
viruses used in this study.
At day 11,MV viral RNAwas detected in a large number of
animals and tissues from both vaccine groups (Table 5), con-
firming the expected time point of the peak of viral replication.
In animals of both one-dose vaccine groups, viral RNA was
mainly detected in secondary lymphoid organs (lymph nodes,
1218 Naunyn-Schmiedeberg's Arch Pharmacol (2012) 385:1211–1225
spleen, Peyer’s patches) and in the non-lymphoid tissues of the
intestine (with themajority of signals detected above the LOD)
and to a lesser extent in the liver, trachea, larynx and urinary
bladder. Viral RNAwas also detected in few animals in lungs,
eyes, adrenals (for animals in both vaccine groups), in ureters
and salivary glands (for the MV1-F4 group) and in several
other organs for the Rouvax group. Importantly, no viral RNA
was detected in the brain, cerebellum, cerebrum, spinal cord
Table 4 Detection of MV RNA in biological fluids/excretions by RT-qPCR at day 11
Treatment group Detection of viral RNA Result infectivity
assay
Signal < LODa Positive signal (+)b
Animals (N) Body fluid Animals (N) Body fluid
NaCl Group 1 – – – – –
Group 4 – – – – –
MV1-F4 Group 2 2 M Faeces – – Negative
Group 5 1 F Urine, vaginal secretion – – Negative
Group 7 – – – – –
Rouvax Group 3 1 F Nasal swab – – Negative
Group 6 1 M Serum, faeces, PBMCs 1 M Throat swab Negative
1 M Nasal swab, faeces
1 F Throat swab, vaginal secretion
Group 8 1 MM PBMCs – – Negative
(M)M/F (mature) male/female; N no. of animals with positive signal in sample/no. of tested animals in that group
a <LOD: RNA signal detected but the number of copies was less than the defined LOD of 100 genome equivalent (geq)/reaction (with 95 % chance
to detect a positive signal).
b +: positive signal, i.e., signal > defined LOD of the RT-qPCR assay (with 95 % probability)
Fig. 1 Anti-MV antibody levels and seroconversion rates. Serum
levels of anti-MV antibodies were measured prior to or after injection
of MV1-F4, Rouvax or saline. Antibody levels were expressed as the
ratio between the optical density (OD) at 490 and at 620 nm. Animals
were considered to be responders if the absorbance exceeded the cut-
off value, for a serum dilution of 1:500. Each line represents one
monkey. Plain and open symbols represent male and female monkeys,
respectively. a Young animals (N06/group) were immunized at day 1
and sacrificed at day 11 (groups 1, 2 and 3). Blood samples were taken
at days 0 and 11. b Young animals (N06/group) were immunized at
days 1, 29 and 57, and sacrificed at day 85 (groups 4, 5 and 6). Blood
samples were taken at days 0, 11, 29, 56, 67 and 85. c Sexually mature
animals (N03/group) were immunized at days 1, 29 and 57 (groups 7
and 8). Blood samples were taken at days 0, 11, 29, 56, 67 and 85
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regions, thalamus and hypothalamus of any animal. No
gender-determined patterns were detected.
At day 85 (28 days after the third dose), viral RNA was
still detectable in the spleen and lymph nodes of some
animals (both vaccine groups), and also in Peyer’s patches
and the intestine (Rouvax group). Low signals were also
detected in the larynx and the trachea (Rouvax group).
No viral RNA was detected in the controls at both time
points of necropsy.
Gross pathology, organ weights and histopathology
Necropsy after either one or three injections revealed no mac-
roscopic findings attributable to either treatment. Recorded
findings were sporadic or common for cynomolgus monkeys
and therefore considered toxicologically irrelevant.
At day 11, the mean absolute and relative spleen weights
of males of both vaccine groups tended to be higher than
for control males (without reaching statistical significance),
Table 5 Detection of MV RNA in organs and tissues by RT-qPCR
Organs/tissues Day 11 Day 85
MV1-F4 — 1 dose
(Group 2)
N
Rouvax — 1 dose
(Group 3)
N
MV1-F4 — 3 doses
(Group 5)
N
Rouvax — 3 doses
(Group 6)
N
Adrenals 1/6<LOD 1/6<LOD – –
Large intestine (caecum/colon/rectum) 2/6+; 2/6<LOD 3/6+; 1/6<LOD – 1/6+
Small intestine (ileum/jejunum/duodenum) 2/6+; 1/6<LOD 4/6+; 1/6<LOD – 1/6<LOD
Eye: retina+lid 1/6<LOD 1/6<LOD – –
Gall bladder – 2/6+ – –
Kidneys – 1/6+ – –
Larynx 1/6+ 2/6+; 1/6<LOD – 1/6<LOD
Liver 3/6<LOD 1/6+; 5/6<LOD – –
Lungs with bronchi 1/6+; 1/6<LOD 1/6<LOD – –
Lymph nodes (cervical) 4/6+ 5/6+ 1/6+ 2/6+; 1/6<LOD
Lymph nodes (iliac) 4/6+; 1/6<LOD 4/6+ 3/6+; 1/6<LOD 2/6+; 2/6<LOD
Lymph nodes (mandibular) 4/6+ 5/6+ 2/6<LOD 4/6+
Lymph nodes (mesenteric) 3/6+; 1/6<LOD 5/6+ 1/6<LOD 3/6+; 2/6<LOD
Lymph nodes (popliteal) 2/6<LOD 2/6+; 1/6<LOD 1/6+ 3/6+
Mammary gland area – 1/6<LOD – –
Mesenteric artery – 1/6+; 1/6<LOD – –
Pancreas – 2/6<LOD – –
Peyer’s patches 2/6+; 1/6<LOD 4/6+ – 1/6+; 1/6<LOD
Salivary glands 2/6<LOD – – –
Skin – 1/6<LOD – –
Pia maters (cervical/lumbar/thoracic) – 1/6<LOD – –
Spleen 4/6+; 1/6<LOD 5/6+ 1/6+; 2/6<LOD 3/6+; 1/6<LOD
Sternum with bone marrow – 2/6<LOD – –
Thymus – 1/6+ – –
Tongue – 1/6<LOD – –
Trachea 2/6<LOD 2/6+; 1/6<LOD – 1/6<LOD
Ureters 1/6+ – – –
Urinary bladder 1/6+; 2/6<LOD 1/6<LOD – –
Uterus corpus + cervix – 1/3<LOD – –
Vagina – 1/3<LOD – –
No detections were made in the remaining organs (aorta, brain, cerebellum, cerebrum, epididymides, femoral bone with articulation, heart,
hypothalamus, injection sites, knee joint, optic nerve, oesophagus, ovaries, oviducts, pituitary gland, prostate, sciatic nerve, seminal vesicles,
skeletal muscle, spinal cord regions, stomach (fundus), testes, thalamus, thyroids and parathyroids) for these groups and time points
N no. of animals with positive signal in tissue sample/no. of tested animals in that group; +/−: + 0 positive signal (signal > defined limit of detection
[LOD] of the RT-qPCR assay [with 95 % probability]). – : no RNA signal detected; <LOD: RNA signal detected but the number of copies was less
than the defined LOD of 100 geq/reaction (with 95 % chance to detect a positive signal)
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which was only observed to a minor extent for the females
of these groups (Table 6). Similar effects were observed for
the cervical lymph nodes. For the iliac lymph nodes, which
were the draining lymph nodes for the injection sites (the
thighs), there was a slight tendency for higher weights in all
Rouvax-treated animals. Mean thymus weights tended to be
lower in both treated male groups than in control groups,
possibly due to high absolute and relative weights of one
control male (129 % and 118 % of group mean values,
respectively). No clear effects of immunization were ob-
served on the thymus weights of females of any group.
At day 85, mean absolute and relative spleen weights of
both vaccine groups were higher than those of controls for
both sexes, which reached statistical significance (p<0.05)
in the Rouvax-treated females. Mean absolute and relative
weights of cervical and iliac lymph nodes tended to be
higher in both groups of vaccinated males as compared to
the control groups, while a high variability in values were
noted for the female groups. Mean thymus weights tended
to be lower in both groups of vaccinated males and in
Rouvax-treated females, as compared to control groups.
None of these differences between groups or sexes,
observed on either day of necropsy, were supported by
macroscopic observations.
For the majority of immunized animals that were sacri-
ficed at days 11 or 85, the increase in the absolute and/or
relative spleen weights could not be directly correlated to
the detection of viral RNA in these spleens in the biodis-
tribution analyses. An increased spleen weight was noted in
some animals for which no viral RNA was detected in the
spleen, and conversely, no increased spleen weight was
observed in some animals for which viral RNAwas detected
in the spleen.
Microscopically, enlargements of the white pulp in the
spleen were occasionally noted in the animals sacrificed at
day 11, in one of the three males and one of the three
females treated with MV1-F4, and in one of the three
control females. This enlargement was primarily due to
generation of germinal centers, and was also noted in the
animals sacrificed on day 85 (in one of the three MV1-F4-
treated males and two of the three Rouvax-treated males). At
both time points, the increased sizes of the white pulp and/or
germinal centers were not necessarily linked to the detection
of viral RNA in the spleens. In addition, no enlargement was
observed in some animals for which viral RNAwas detected
in the spleen. Furthermore, minimally increased germinal
center sizes and/or numbers were occasionally noted in
mandibular lymph nodes in two of the three MV1-F4-
treated males sacrificed on day 11. Although this was also
seen in one of three control females sacrificed on day 85,
a relationship to treatment could not be excluded. This
effect was rarely seen in iliac, cervical or popliteal lymph
nodes. The higher absolute and relative weights of cer-
vical and iliac lymph nodes recorded in males of both
vaccine groups on day 85 did not correlate with any consistent
microscopic changes.
No relevant microscopic changes were observed at the
injection sites on both days of necropsy. All other microscopic
findings occurred at equal frequency across groups and/or
were within the normal laboratory ranges for this species,
and were therefore considered as toxicologically irrelevant.
Moreover, no effects suggestive of MV infection (follicular
Table 6 Treatment-related
organ weight differences when
compared to controls (%)
Results are differences
(expressed as percentages) of the
mean weight of three animals
per vaccine group, as compared
to those of control groups.




from control groups (with
significance based on values,
not on percentages)
Necropsy Day 11 (one-dose groups) Day 85 (three-dose groups)
Sex Male Female Male Female










Body weight (%) +10 −1 −5 −11 +3 −8 −9 +8
Spleen
Absolute (%) +36 +53 +7 −6 +18 +7 +2 +72
Relative (%) +23 +45 +14 +6 +13 +16 +12 +60*
Cervical LN
Absolute (%) +52 +16 −21 −40 +81 +146 −2 +7
Relative (%) +37 +26 −15 −33 +69 +167 +6 −3
Iliac LN
Absolute (%) −4 +11 −9 +4 +33 +36 −40 +34
Relative (%) −9 +20 0 +17 +30 +47 −34 +24
Thymus
Absolute (%) −20 −26 +19 −7 −8 −42 +4 −24
Relative (%) −27 −23 +29 +7 −12 −39 +15 −28
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necrosis within the hair follicles, proliferative and necrotizing
bronchointerstitial pneumonia, thymus atrophy or Warthin–
Finkeldey cells within the lymph nodes or spleen) were found.
In addition, there was no evidence of subacute sclerosing
panencephalitis (a rare syndrome in humans occurring after
infection with wild-type MV stains, characterized by progres-
sive gliosis, demyelination and neuronal loss).
Discussion
In order to support the clinical development of the MV1-F4
vaccine, we have compared the toxicology, biodistribution
and shedding profiles of the HIV-1 candidate vaccine
MV1-F4 to those of the parental Schwarz vaccine strain,
using a cynomolgus macaque model. In addition, the
results may serve to increase our knowledge of the toxicity
or in vivo tropism of MV vectors or vaccine strains, which
has been the focus of few preclinical studies to date (e.g.,
de Vries et al. 2010; Lemon et al. 2011; Myers et al. 2007;
Peng et al. 2003).
Our data show that no shedding of infectious virus was
observed for either of the two vaccines. Furthermore, no
toxic effect in relation to the MV vaccination was found
with these vaccines. One or three IM injections of a full
human dose of MV1-F4 or of the reference vaccine were
well tolerated and induced no clinical symptoms of local or
systemic reactogenicity. For both vaccines, virus replication
was predominantly observed in secondary lymphoid organs
(including spleens, Peyer’s patches and all major lymph
nodes) and to a lesser extent in epithelium-rich tissues
(including intestine, larynx, trachea and urinary bladder)
and liver, which were thus designated as potential target
organs for intrinsic toxicity of the vaccines. However, no
gross or histopathological effects indicative of toxicity were
observed in these target organs, or in any other organs.
Mean spleen weights were increased after three doses of
either vaccine, which corresponded in some animals with
enlargements of the white pulp, due to generation or growth
of germinal centers. This effect likely resulted from immune
activation of the secondary lymphoid organs by the vac-
cines, which has also been observed in other preclinical
studies (Sheets et al. 2006; Speijers et al. 1988). It is less
likely that local virus replication in these organs has caused
the increased spleen weights, as no clear relationship be-
tween increased spleen weights, enlargements of the white
pulp and the presence of viral RNA in the spleens could be
established. All other observations were considered to be
unrelated to treatment, as they occurred incidentally, without
correlation between genders, or at similar frequencies in
control and immunized animals.
The occasional reductions in food consumption had no
impact on body weights and were not considered to be
indicative of systemic toxicity. For DNA plasmid vaccines,
it has been observed that food consumption data and body
weights did not correlate with toxicity or other findings
(Sheets et al. 2006). A similar conclusion could potentially
be drawn for recombinant live-attenuated vaccines such as
MV1-F4.
The only clinical pathological finding for MV1-F4 treat-
ment groups was a slight but statistically significant de-
crease of the aPTT (but not of the PT) for males on day
56. However, shortening of the aPTT has generally little
clinical relevance and may be associated with suboptimal
sample collection or processing (Adcock et al. 1998; Awad
et al. 2006). Therefore this is not considered indicative of
coagulation abnormalities of toxicological relevance. We
also observed that on day 85, the mean CK activity for
Rouvax-treated males was significantly higher than for con-
trol males. Elevated CK values are used as a marker of
injury, heart attack, severe muscle breakdown, muscular
dystrophy or acute renal failure (Lott and Abbott 1986).
None of these conditions were observed for the two males
involved, and urinalysis showed no treatment-related effect
for either vaccine. In addition, no elevated CK activity was
found in these animals on previous time points. Possibly
these elevations reflect the effects of IM-delivered sedation
for ophthalmology on day 84. This effect is commonly seen
in preclinical studies (Stewart et al. 2008) and is therefore
not considered to be an adverse reaction to treatment.
Cell tropism for vaccine and wild-type MV strains is
largely determined by virus entry (Tatsuo et al. 2000a).
Wild-type MV, which use predominantly SLAM/CD150
expressed on activated immune cells (Tatsuo et al. 2000b),
is known to mainly replicate in lymphoid organs and epi-
thelial tissues such as the skin, respiratory tract, intestine
and urinary bladder (Griffin 2007; Takeda 2008). Recent
studies suggest that after aerosol infection, wild-type MV
initially targets macrophages and dendritic cells in alveolar
tissues, which is followed by replication in regional lymph
nodes and systemic spreading to lymphoid organs (Lemon
et al. 2011). How MV infects CD150-negative epithelial
cells remains largely unclear, although putative epithelial
receptors have recently been described (Watanabe et al.
2010). As MV vaccine strains use the ubiquitous CD46
receptor in addition to the receptors used by wild-type MV
(Dorig et al. 1993), the vaccine strains were expected to
exhibit a wider tropism than that documented previously for
wild-type MV (Griffin 2007; Lemon et al. 2011; Takeda
2008). However, in macaques infected intratracheally or by
aerosol with wild-type or attenuated (Edmonston tag) re-
combinant MV, only the pathogenic MV caused significant
viremia and widespread distribution. The attenuated MV
had a restricted systemic spread and was rarely detected in
lymphoid tissues (de Vries et al. 2010), in contrast to obser-
vations in the current study. Our data seem to be more
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aligned with studies in mice immunized intraperitoneally or
intravenously with an attenuated oncolytic (Edmonston) re-
combinant strain, in which infected cells were mainly detected
in secondary lymphoid organs, liver and lungs (Myers et al.
2007; Peng et al. 2003). These disparities between studies
may be explained by differences in administration routes,
MV strains or methods of MV detection.
The RT-qPCR results for tissues and biological fluids
confirm a peak of replication around 10 days after the first
dose, supporting other studies in monkeys with wild-type or
attenuated MV strains (Auwaerter et al. 1999; Pan et al.
2005; Permar et al. 2003). This resembles the clinical situ-
ation, as vaccine-induced peaks are known to occur a few
days before those induced by natural infection taking place
between 11 and 14 days after exposure (Strebel et al. 2004).
We observed that viral clearance for both vaccines was not
fully completed at 28 days after the third dose, since viral
RNA was still detectable in lymphoid and epithelium-rich
tissues. This is consistent with an earlier report showing that
MV RNA remained detectable in monkeys for 4–5 months
(in this case, in PBMCs), even though clearance of viremia
occurred within 14 or 29 days (Pan et al. 2005).
An additional study objective was to assess the potential of
virus shedding of the MV1-F4 vaccine (in parallel to that of
the reference vaccine). In natural infection, MV can be isolat-
ed from urine up to 10 days after rash onset (Gresser and Katz
1960), and viral RNA can be detected in PBMC and naso-
pharingeal specimens up to 100 days after rash onset (Riddell
et al. 2007). The few known studies of shedding by attenuated
MV vectors report detection of (Edmonston) viral RNA in
buccal swabs frommonkeys (after intravenous administration;
Myers et al. 2007), but no detection in human urine or saliva
(after intraperitoneal administration; Galanis et al. 2010).
Consistent with reports of detection of viral RNA from atten-
uated MV vaccine strains in human urine up to 14 days after
vaccination (Rota et al. 1995), we detected MV1-F4-derived
RNA in urine at day 11. Infectious viral particles from MV
vaccines have rarely been found in human throat or nasopha-
ryngeal secretions, and there is only one reported case of
isolation of (Schwarz) MV vaccine virus from throat swabs
(Morfin et al. 2002). While we detected viral RNA from both
vaccines at the peak of viremia in a few samples such as throat
and nasopharingal swabs, none of these contained infectious
virus at a LOD of 10 CCID50/well (with 95 % probability).
Therefore, transmission of MV1-F4 virus between persons is
considered unlikely to occur, and has also never been docu-
mented previously for any of the current measles vaccines
(WHO 2009).
The immunogenicity of the MV1-F4 candidate vaccine
was not investigated in detail in the current study, as our study
was primarely designed to assess the toxicology, biodistribu-
tion and shedding profiles of the candidate vaccine. However,
immune responses directed against the F4 transgene were
characterized in a separate study using the same animal model
(MV-seronegative cynomolgus macaques). In the latter study,
the MV1-F4 candidate vaccine was shown to induce F4-
specific CD4+ and CD8+ T cell responses, as well as antibody
responses to F4 (manuscript in preparation).
In conclusion, while viral dissemination was observed in
various organs, no shedding of infectious viral particles was
noted, and no toxic effect in relation to the MV vaccination
was found following one or three IM injections with a
clinically relevant dose of MV1-F4, with the same outcomes
for the (Schwarz) measles comparator vaccine. Moreover,
either vaccine virus replicated predominantly in secondary
lymphoid organs and, to a lesser extent, in epithelium-rich
tissues. Thus, as expected, introduction of the F4 transgene
did not change the toxicological profile, shedding capacity
or tropism of the parental strain.
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